| Literature DB >> 32909468 |
Yijin Hong1, Chunmei Wu1, Biyu Wu1.
Abstract
This research aimed to investigate the effects of resistance exercise on symptoms, physical function, and quality of life (QoL) in gastrointestinal cancer patients undergoing chemotherapy. Patients were quasi-randomly divided into the resistance exercise group and the relaxation control group, and machine-based resistance exercise was performed twice a week for 12 weeks under the guidance of experienced therapists. The QoL of patients was analyzed by EORTC-QLQ-C30. Resistance exercise training significantly reduced the incidences of lack of energy (inter-group P = .011), nausea (inter-group P = .007), acid reflux (inter-group P = .042), and back pain (inter-group P = .0009). Twelve weeks of resistance exercise training significantly elevated the muscular strength of leg press (inter-group P = .021) and leg extension (inter-group P = .041), and the muscular endurance of leg press (inter-group P = .005). The participants' performance in 6-m fast walk (inter-group P = .008), 6-m backwards walk (inter-group P = .016), and chair rise (inter-group P = .031) were dramatically improved. Fatigue (inter-group P = .024) and appetite loss (inter-group P = .012) in the resistance exercise group were significantly lower than the relaxation control group. In conclusion, the beneficial effects of resistance exercise on symptoms, physical function and QoL in gastrointestinal cancer patients undergoing chemotherapy were demonstrated. Resistance exercise training reduced the incidences of nausea and acid reflux, improved physical function, and alleviated fatigue and appetite loss in gastrointestinal cancer patients undergoing chemotherapy.Entities:
Keywords: chemotherapy; gastrointestinal cancer; quality of life; resistance exercise
Year: 2020 PMID: 32909468 PMCID: PMC7493268 DOI: 10.1177/1534735420954912
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.Research framework of this study.
Demographic and Clinical Characteristics of the Patients Analyzed.
| Characteristics | Study group |
| |
|---|---|---|---|
| Resistance exercise (n = 94) | Relaxation control (n = 96) | ||
| Age (years) | 55.4 ± 11.6 | 52.3 ± 12.4 | .352 |
| Male gender | 54 (57.4 %) | 51 (53.1 %) | .563 |
| Body weight (kg) | 69.6 ± 14.3 | 71.3 ± 15.4 | .472 |
| BMI | 26.3 ± 4.9 | 25.9 ± 4.4 | .318 |
| Smoking before diagnosis | 30 (31.9 %) | 28 (29.2 %) | .753 |
| Still smoking at baseline | 10 (10.6 %) | 12 (12.5 %) | .821 |
| Tumor diagnosis | |||
| Rectal cancer | 23 (24.5 %) | 20 (20.8 %) | .605 |
| Cholangiocellular cancer | 17 (18.1 %) | 22 (22.9 %) | .474 |
| Colon cancer | 29 (30.8 %) | 24 (25 %) | .419 |
| Gastric cancer | 18 (19.1 %) | 18 (18.8 %) | 1.000 |
| Pancreatic cancer | 7 (7.5 %) | 12 (12.5 %) | .334 |
| Tumor Stage TNM | |||
| II | 19 (20.2 %) | 17 (17.7 %) | .713 |
| III | 49 (52.1 %) | 56 (58.3 %) | .466 |
| IV | 26 (27.7 %) | 23 (24.0 %) | .620 |
| Previous tumor resection | 74 (78.7 %) | 70 (72.9 %) | .399 |
| Time between tumor resection and recruitment (days) | 63.6 ± 18.1 | 55.7 ± 16.3 | .248 |
| Concomitant radiotherapy | 23 (24.5 %) | 15 (15.6 %) | .149 |
| Days since first chemotherapy | 56.3 ±17.6 | 61.4 ± 19.6 | .276 |
| Chemotherapy protocol | |||
| Oxaliplatin + capecitabine | 36 (38.3 %) | 31 (32.3 %) | .448 |
| Fluorouracil + leucovorin | 21 (22.3 %) | 26 (27.1 %) | .503 |
| Oxaliplatin + leucovorin + fluorouracil | 17 (18.1 %) | 23 (23.9 %) | .375 |
| Others | 20 (21.3 %) | 16 (16.7 %) | .462 |
BMI, body mass index.
Values were expressed as n (percentage) or mean ± SD.
Incidences of Symptoms Reported for Patients Included in The Trial.
| Symptoms | Study group | |||
|---|---|---|---|---|
| Resistance exercise (n = 94) | Relaxation control (n = 96) | |||
| Loss of appetite | Baseline | 49 (52.1 %) | 52 (54.2 %) | .885 |
| Post-intervention | 44 (46.8 %) | 56 (58.3 %) | .146 | |
| 0.559 | 0.663 | |||
| Lack of energy | Baseline | 61 (64.9 %) | 58 (60.4 %) | .551 |
| Post-intervention | 50 (53.2 %) | 69 (71.9 %) |
| |
| 0.138 | 0.127 | |||
| Nausea | Baseline | 54 (57.4 %) | 58 (60.4 %) | .768 |
| Post-intervention | 46 (48.9 %) | 66 (68.8 %) |
| |
| 0.306 | 0.291 | |||
| Mouth ulcers | Baseline | 35 (37.2 %) | 40 (41.7 %) | .556 |
| Post-intervention | 33 (35.1 %) | 46 (47.9 %) | .079 | |
| 0.879 | 0.468 | |||
| Acid reflux | Baseline | 50 (53.2 %) | 45 (46.9 %) | .468 |
| Post-intervention | 40 (42.6 %) | 56 (58.3 %) |
| |
| 0.189 | 0.148 | |||
| Cough | Baseline | 37 (39.4 %) | 35 (36.5 %) | .765 |
| Post-intervention | 30 (31.9 %) | 42 (43.8 %) | .102 | |
| 0.361 | 0.377 | |||
| Back pain | Baseline | 32 (34.1 %) | 30 (31.3 %) | .757 |
| Post-intervention | 18 (19.2 %) | 40 (41.7 %) |
| |
|
| 0.177 | |||
| Fever | Baseline | 23 (24.5 %) | 26 (27.1 %) | .741 |
| Post-intervention | 18 (19.1 %) | 25 (26.1 %) | .299 | |
| 0.480 | 0.871 | |||
| Alopecia | Baseline | 34 (36.2 %) | 30 (31.3 %) | .539 |
| Post-intervention | 27 (28.7 %) | 36 (37.5 %) | .219 | |
| 0.350 | 0.448 | |||
Values were expressed as n (percentage, %).
Chi square test. Bold values indicate P < 0.05.
Effects of Resistance Exercise (EX) on Physical Performance, Muscular Strength, and Endurance Measures for Patients Included in The Trial.
| Variables | Study group | |||
|---|---|---|---|---|
| Resistance exercise (n = 94) | Relaxation control (n = 96) | |||
| Muscular strength (kg) | ||||
| Chest press | Baseline | 35.2 ± 17.2 | 36.1 ± 16.9 | .256 |
| Post-intervention | 39.4 ± 16.3 | 32.6 ± 17.8 | .315 | |
| 0.417 | 0.126 | |||
| Seated row | Baseline | 65.3 ± 21.5 | 66.8 ± 22.9 | .523 |
| Post-intervention | 67.1 ± 19.6 | 63.9 ± 23.1 | .428 | |
| 0.371 | 0.442 | |||
| Leg press | Baseline | 118.4 ± 42.3 | 121.6 ± 39.5 | .294 |
| Post-intervention | 158.3 ± 41.7 | 112.8 ± 40.1 |
| |
|
| 0.086 | |||
| Leg extension | Baseline | 54.8 ± 18.6 | 55.9 ± 19.2 | .548 |
| Post-intervention | 69.8 ± 23.3 | 51.7 ± 24.8 |
| |
|
| 0.215 | |||
| Muscular endurance (rep) | ||||
| Chest press | Baseline | 9.7 ± 3.8 | 10.5 ± 4.8 | .263 |
| Post-intervention | 12.4 ± 4.2 | 9.5 ± 5.2 | .114 | |
| 0.174 | 0.632 | |||
| Leg press | Baseline | 11.5 ± 5.1 | 10.2 ± 6.3 | .424 |
| Post-intervention | 22.4 ± 6.8 | 8.6 ± 7.2 |
| |
|
| 0.173 | |||
| Physical performance (s) | ||||
| 6-m usual walk | Baseline | 4.5 ± 0.7 | 4.2 ± 0.6 | .328 |
| Post-intervention | 3.9 ± 0.5 | 4.6 ± 0.7 |
| |
| 0.264 | 0.327 | |||
| 6-m fast walk | Baseline | 2.9 ± 0.3 | 2.8 ± 0.4 | .137 |
| Post-intervention | 2.6 ± 0.4 | 3.1 ± 0.6 |
| |
|
| 0.216 | |||
| 6-m backwards walk | Baseline | 14.6 ± 3.2 | 14.4 ± 3.8 | .527 |
| Post-intervention | 11.8 ± 2.6 | 15.2 ± 2.9 |
| |
|
| 0.365 | |||
| 400-m walk | Baseline | 227.1 ± 24.7 | 231.4 ± 27.1 | .448 |
| Post-intervention | 222.4 ± 28.2 | 238.3 ± 24.9 | .116 | |
| 0.292 | 0.491 | |||
| Chair rise | Baseline | 10.7 ± 1.3 | 10.3 ± 1.5 | .554 |
| Post-intervention | 9.2 ± 1.6 | 10.9 ± 1.2 |
| |
|
| 0.117 | |||
Values were expressed as mean ± SD. Bold values indicate P < 0.05.
Effects of Resistance Exercise (EX) on Quality of Life (EORTC-QLQ-C30).
| Outcomes | Study group | |||
|---|---|---|---|---|
| Resistance exercise (n = 94) | Relaxation control (n = 96) | |||
| Quality of life-EORTC QLQ30 (scale 0–100) | ||||
| Global QoL | Baseline | 56.8 ± 19.5 | 58.6 ± 20.3 | .486 |
| Post-intervention | 60.3 ± 21.7 | 55.2 ± 22.6 | .116 | |
| 0.427 | 0.271 | |||
| Physical function | Baseline | 83.6 ± 15.7 | 84.7 ± 18.2 | .724 |
| Post-intervention | 86.3 ± 17.4 | 72.4 ± 15.9 |
| |
| 0.458 |
| |||
| Emotional function | Baseline | 69.2 ± 22.7 | 67.5 ± 19.9 | .552 |
| Post-intervention | 68.3 ± 18.6 | 68.7 ± 21.6 | .528 | |
| 0.637 | 0.485 | |||
| Role function | Baseline | 62.3 ± 24.7 | 64.1 ± 21.3 | .52 |
| Post-intervention | 66.7 ± 19.4 | 54.9 ± 17.9 |
| |
| 0.624 |
| |||
| Cognitive function | Baseline | 79.4 ± 19.5 | 81.7 ± 20.6 | .316 |
| Post-intervention | 74.1 ± 22.7 | 78.3 ± 21.8 | .411 | |
| 0.226 | 0.396 | |||
| Social function | Baseline | 72.2 ± 24.1 | 68.9 ± 20.3 | .363 |
| Post-intervention | 75.8 ± 23.4 | 60.1 ± 19.2 |
| |
| 0.393 | 0.058 | |||
| Sleep disturbance | Baseline | 29.7 ± 17.8 | 32.2 ± 22.3 | .227 |
| Post-intervention | 27.2 ± 19.3 | 34.5 ± 21.0 | .378 | |
| 0.496 | 0.525 | |||
| Dyspnea | Baseline | 25.1 ± 16.8 | 22.4 ± 18.5 | .117 |
| Post-intervention | 26.7 ± 17.9 | 31.9 ± 20.3 | .165 | |
| 0.615 |
| |||
| Nausea and vomiting | Baseline | 22.5 ± 10.9 | 23.2 ± 9.8 | .341 |
| Post-intervention | 19.5 ± 11.3 | 26.6 ± 12.5 | .287 | |
| 0.373 | 0.416 | |||
| Appetite loss | Baseline | 18.3 ± 8.9 | 17.6 ± 7.5 | .663 |
| Post-intervention | 12.2 ± 7.1 | 22.6 ± 6.9 |
| |
| 0.195 | 0.274 | |||
| Fatigue | Baseline | 21.4 ± 9.7 | 19.9 ± 8.7 | .438 |
| Post-intervention | 14.1 ± 7.3 | 24.3 ± 10.3 |
| |
|
| 0.142 | |||
QoL, quality of life.
Values were expressed as mean (SD). Bold values indicate P < 0.05.